Raphael Pharmaceutical (RAPH) Free Cash Flow (2020 - 2025)
Raphael Pharmaceutical (RAPH) posted Free Cash Flow of $46000.0 for Q4 2025, up 370.59% sequentially from -$17000.0 in Q3 2025, and up 174.19% YoY from $16776.5 in Q4 2024.
Raphael Pharmaceutical (RAPH) Free Cash Flow (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical has reported Free Cash Flow for 6 years, with the latest figure at $46000.0 in Q4 2025.
- Quarterly Free Cash Flow rose 174.19% year-over-year to $46000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$210000.0 (up 60.6% YoY) and the FY2025 annual result came in at -$210000.0, up 60.53% from the prior year.
- Free Cash Flow grew to $46000.0 in Q4 2025 per RAPH's latest filing, from -$17000.0 in the prior quarter.
- Over five years, Free Cash Flow peaked at $46000.0 in Q4 2025 and troughed at -$704000.0 in Q4 2021.
- A 5-year average of -$206200.0 and a median of -$191000.0 in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow slumped 386.59% in 2023, then surged 174.19% in 2025.
- Over 5 years, Free Cash Flow stood at -$704000.0 in 2021, then jumped by 60.65% to -$277000.0 in 2022, then soared by 68.23% to -$88000.0 in 2023, then rose by 29.55% to -$62000.0 in 2024, then jumped by 174.19% to $46000.0 in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered $46000.0, -$17000.0, and -$30000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 307.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 538.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 1.14 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 205.60 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 329.00 Mn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 128.60 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 244.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Mar 31, 2025 | -209,000.00 |
| Mar 31, 2025 | -209,000.00 |
| Dec 31, 2024 | -62,000.00 |
| Dec 31, 2024 | -62,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Jun 30, 2024 | -218,000.00 |
| Jun 30, 2024 | -218,000.00 |
| Mar 31, 2024 | -173,000.00 |
| Mar 31, 2024 | -173,000.00 |
| Dec 31, 2023 | -88,000.00 |
| Dec 31, 2023 | -88,000.00 |
| Sep 30, 2023 | -501,000.00 |
| Sep 30, 2023 | -501,000.00 |